查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1931198

避孕药物输送装置市场依产品类型、技术、最终用户和通路划分，全球预测（2026-2032年）

Contraceptive Drug Eluting Devices Market by Product Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年避孕药物释放装置市场规模为6.4264亿美元，预计到2026年将成长至7.0089亿美元，到2032年将达到12.793亿美元，复合年增长率为10.33%。

关键市场统计数据
基准年 2025 6.4264亿美元
预计年份：2026年 7.089亿美元
预测年份 2032 12.793亿美元
复合年增长率 (%) 10.33%

缓释避孕装置融合了医疗设备工程和生殖医学，将缓释药物技术与植入式或阴道内给药平台结合，以优化避孕效果、便利性和依从性。过去十年，聚合物科学、装置传输机制和以患者为中心的护理模式的不断进步，彻底改变了临床医生和患者对长效可逆避孕方法的评估方式，使这些技术成为各种临床环境中的核心选择。

随着避孕选择从临时性生育计画转向终身生育计划，相关人员在寻求符合生活方式、生育次数和年龄相关偏好的产品特性时，更加重视产品的可靠性、可逆性和安全性。同时，监管路径和临床试验设计也在不断发展，更加重视实际应用效果和长期安全性数据，从而重塑了产品开发週期。鑑于药物释放性能的稳定性需要特殊的聚合物和无菌工艺，供应链的韧性和生产品质在采购决策中扮演越来越重要的角色。

综上所述，这些趋势凸显了将临床价值提案与监管应对力和生产规模化相结合的策略重要性。本导论部分概述了技术、临床和商业性方面的内容，为后续章节奠定了基础，并阐述了製造商、医疗服务提供者和支付方应如何解读医疗器材的差异化和应用路径。

透过改变临床实务、聚合物创新、数位整合和个人化医疗，实现避孕药物释放装置的变革性转型。

生物可降解和不可降解聚合物平台目前支援更广泛的释放曲线和持续时间，使多种产品原型能够更好地满足患者偏好和临床应用需求。同时，植入和取出技术的改进，以及针对医护人员的培训模式，正在降低先前限制其广泛应用的程序障碍。

美国在2025年推出或扩大关税措施对供应链、製造选择、临床应用以及跨境医疗设备分销的累积影响

美国在2025年推出或扩大的关税措施对避孕药物缓释装置的价值链产生了一系列复杂的影响，其累积效应远不止于进口关税本身。影响原料聚合物、专用组件和成品装置的关税可能会增加到岸成本，并促使采购商和製造商重新评估筹资策略和整体拥有成本。为此，企业可能会加快供应商网路的多元化，寻求在美洲的近岸外包机会，或透过重新谈判长期供应商合约来寻求投入价格的稳定。

关键细分洞察揭示了影响产品类型、聚合物技术、终端用户环境、分销管道和人口统计群体等因素，从而推动了产品采用趋势的发展。

市场区隔揭示了需求、临床适用性和营运优先事项在产品、技术、终端用户、分销和人口统计等维度上的交汇点。依产品类型细分，可区分植入、子宫内避孕系统和避孕环，每种产品都有其独特的持续时间和使用特性。植入的评估週期从短到长不等，例如3年和5年的设计。子宫内避孕系统涵盖了常见的3年、5年和7年使用週期选择。而避孕环则设计为每月或每季更换一次。这些产品差异会影响临床咨询、追踪频率和器材生命週期等方面的考量。

重点区域洞察，着重分析需求驱动因素、政策趋势、供应链韧性以及主要区域的病患就医差异

区域趋势导致需求模式、监管压力和供应链限制存在差异，製造商必须应对这些差异。在美洲，完善的临床基础设施以及对生殖健康的政策重点推动了相关技术在诊所和医院管道的广泛应用；同时，供应链韧性倡议和生产奖励正在影响特种聚合物和无菌组装的采购决策。

企业策略和竞争动态影响产品创新、製造地、监管路径和伙伴关係模式。

避孕药物输送装置领域的主要企业正朝着一系列策略重点迈进，这些重点将塑造其竞争动态。产品差异化取决于聚合物的选择和释放动力学、植入和取出操作的便利性以及整合的患者支援服务，包括数位追踪和依从性工具。那些早期投资于可扩展的无菌生产、完善的品质系统和多元化采购的企业，将在产品上市速度和稳定的利润率方面获得优势。

为产业领导者提供切实可行的建议，以加速创新、加强供应链、协调监管策略并扩大患者获取途径。

我们鼓励产业领导者采取务实的分阶段方法，兼顾短期营运韧性和长期创新。首先，应优先考虑供应链韧性，并透过识别关键聚合物和组件供应商、选择备用供应商以及评估区域製造地的可行性来降低关税和物流风险。投资于检验的契约製造关係和冗余灭菌能力，既能降低中断风险，又能维持资本效率。

调查方法包括资料收集、初步访谈、临床和监管资讯、供应链图谱绘製以及定性情境建构。

本研究结合了结构化一手访谈、有针对性的二手资料以及临床、监管和供应链资料的整合，建构了强有力的证据基础。一手研究包括对临床医生、采购专业人员、聚合物供应商、契约製造和监管顾问进行结构化访谈，以收集关于医疗设备可用性、采购障碍和生产限制的第一手观点。二级资讯来源包括同行评审的临床文献、监管指导文件、专利趋势信号和临床检验註册信息，以对产品性能和核准途径进行三角验证。

全面概述了避孕药物输送装置未来发展的临床、技术和商业性影响。

总之，避孕药物缓释装置兼具临床价值、材料创新和商业性机会，但要充分发挥其潜力，需要在产品开发、监管策略和供应链管理等方面通力合作。可生物降解和不可生物降解聚合物的进步拓展了药物缓释持续时间和使用者体验的选择范围，而不断发展的护理模式和数位化支持则丰富了咨询和追踪途径。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的避孕药物输送装置市场

  • 植入
  • 子宫内系统
  • 阴道环

9. 依技术分類的避孕药物输送装置市场

  • 可生物降解聚合物
    • PLA
    • PLGA
  • 不可生物降解聚合物
    • 乙烯-醋酸乙烯酯
    • 硅酮

10. 依最终用户分類的避孕药物输送装置市场

  • 诊所
    • 计划生育中心
    • 妇产科诊所
  • 居家照护
  • 医院
  • 专业中心

11. 依分销管道分類的避孕药物输送装置市场

  • 离线
  • 在线的

12. 依地区分類的避孕药物输送装置市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 依组别分類的避孕药物输送装置市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国避孕药物输送装置市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国避孕药物传输装置市场

16. 中国：避孕药物输送装置市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actavis plc
  • Agile Therapeutics, Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Evofem Biosciences, Inc.
  • GlaxoSmithKline plc
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Warner Chilcott plc
Product Code: MRR-7B550E008DB2

The Contraceptive Drug Eluting Devices Market was valued at USD 642.64 million in 2025 and is projected to grow to USD 700.89 million in 2026, with a CAGR of 10.33%, reaching USD 1,279.30 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 642.64 million
Estimated Year [2026] USD 700.89 million
Forecast Year [2032] USD 1,279.30 million
CAGR (%) 10.33%

Contraceptive drug-eluting devices are at the intersection of medical device engineering and reproductive health therapeutics, combining sustained-release pharmacology with implantable or intravaginal platforms to optimize efficacy, convenience and adherence. Over the past decade, incremental improvements in polymer science, device delivery mechanisms and patient-centric care models have transformed how clinicians and patients evaluate long-acting reversible contraception, making these technologies core options across diverse care settings.

As attention moves from episodic contraception to lifecycle reproductive planning, stakeholders are prioritizing reliability, reversibility and safety while also demanding product attributes that align with lifestyle, parity and age-related preferences. Concurrently, regulatory pathways and clinical trial design have evolved to emphasize real-world performance and long-term safety data, reshaping product development timelines. Supply chain resilience and manufacturing quality are increasingly visible factors in procurement decisions, given the specialized polymers and sterile processes required for consistent drug-eluting performance.

Taken together, these forces highlight the strategic importance of aligning clinical value propositions with regulatory readiness and manufacturing scalability. The introduction frames the technical, clinical and commercial dimensions that inform subsequent sections, establishing a foundation for how manufacturers, providers and payers should interpret device differentiation and adoption pathways.

Transformative shifts redefining contraceptive drug-eluting devices through clinical practice changes, polymer innovations, digital integration and personalized care

Several transformative shifts are reshaping the landscape for contraceptive drug-eluting devices, driven by advances in polymer chemistry, digital health integration and evolving clinical expectations. Biodegradable and non-biodegradable polymer platforms now support a wider range of release profiles and durations, enabling multiple product archetypes that better match patient preferences and clinical use cases. At the same time, improvements in insertion and removal techniques, coupled with provider training models, are lowering procedural barriers that historically limited uptake.

Simultaneously, the rise of telehealth and remote care pathways is altering how patients access counseling, follow-up and adverse event management, creating opportunities for hybrid models that blend clinic-based procedures with home-based support. Regulators are adapting to this reality by placing greater emphasis on post-market surveillance and real-world evidence, prompting manufacturers to design data-collection features and registry partnerships into launch plans. Supply chain diversification and nearshoring initiatives are also accelerating, prompted by geopolitical uncertainty and the need to secure specialized polymers and sterile manufacturing capacity.

Consequently, competitive differentiation increasingly rests on integrated value propositions that combine clinical performance, patient experience and operational resilience. As a result, product roadmaps, partnership strategies and go-to-market plans are being recalibrated to capture both short-term clinical demand and longer-term population health objectives.

Cumulative effects of United States tariff measures in 2025 on supply chains, manufacturing choices, clinical access and cross-border device distribution

United States tariff measures introduced or expanded in 2025 present a complex set of implications for the contraceptive drug-eluting device value chain, with cumulative effects that extend beyond headline import duties. Tariffs that affect raw polymer feedstocks, specialty components and finished devices can increase landed costs, prompting buyers and manufacturers to reassess sourcing strategies and total cost of ownership. In response, firms may accelerate diversification of supplier networks, pursue nearshoring opportunities in the Americas, or renegotiate long-term supplier contracts to stabilize input prices.

These trade policy shifts also influence manufacturing location decisions. Companies dependent on high-volume, low-cost production in Asia may evaluate the trade-offs of relocating assembly or critical steps closer to end markets to mitigate tariff exposure and reduce lead-time variability. At the same time, transitional supply chain moves require investment in validation, regulatory filings and sterile manufacturing capacity, which can extend product timelines unless planned proactively.

Clinicians and healthcare purchasers may face short-term price pressure that affects formulary placement, procurement cycles and procurement negotiations. Moreover, tariff-driven supply constraints can amplify the value of contract manufacturing relationships and strategic inventories, particularly for devices using specialized biodegradable polymers such as PLA and PLGA or non-biodegradable materials like ethylene vinyl acetate and silicone. Ultimately, prudent scenario planning and proactive supply chain resilience measures will be essential to manage the operational and commercial consequences of tariff changes while maintaining patient access and manufacturer viability.

Key segmentation insights revealing product types, polymer technologies, end-user settings, distribution channels and demographic cohorts shaping adoption

Segmentation reveals where demand, clinical fit and operational priorities converge across product, technology, end user, distribution and demographic dimensions. Product type segmentation distinguishes implants, intrauterine systems and vaginal rings, each with distinct duration and dosing characteristics: implants are evaluated across shorter and longer durations such as three-year and five-year designs, intrauterine systems span options commonly studied across three-, five- and seven-year durations, while vaginal rings are designed either for monthly or quarterly change intervals. These product distinctions drive clinical counseling, follow-up cadence and device lifecycle considerations.

Technology segmentation differentiates biodegradable polymer platforms from non-biodegradable substrates. Within biodegradable polymers, polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) are central to sustained-release strategies, offering controlled resorption profiles. Non-biodegradable polymers such as ethylene vinyl acetate and silicone deliver stable matrices for extended hormone delivery, with distinct implications for removal procedures and long-term device behavior.

End-user segmentation highlights the settings where devices are delivered and supported: clinics-including family planning centers and OB-GYN clinics-remain primary access points, complemented by hospitals, specialty centers and expanding models for home care follow-up. Distribution channels span hospital pharmacies, online pharmacies and retail pharmacy networks, each with unique logistical and regulatory checkpoints. Demographic segmentation emphasizes the importance of age cohorts, frequently grouped as 15-24, 25-34, 35-44 and 45+, and parity distinctions between multiparous and nulliparous patients. Together, these segmentation layers inform product positioning, messaging, training requirements and post-market evidence strategies because they determine clinical relevance, usability expectations and reimbursement pathways.

Key regional insights highlighting demand drivers, policy dynamics, supply chain resilience and patient access differences across major global regions

Regional dynamics create differentiated demand patterns, regulatory pressures and supply chain constraints that manufacturers must navigate. In the Americas, a combination of established clinical infrastructure and policy focus on reproductive health supports broad adoption across clinic and hospital channels, while supply chain resilience initiatives and manufacturing incentives are influencing sourcing decisions for specialized polymers and sterile assembly.

Europe, Middle East & Africa presents a more heterogeneous landscape where regulatory frameworks vary substantially and affordability considerations shape procurement pathways; in some markets centralized public procurement and reimbursement mechanisms accelerate scale-up, whereas in others fragmented payer systems and distribution challenges demand tailored market entry strategies. Meanwhile, policy debates around reproductive health access and import regulation can materially affect timing and uptake.

Asia-Pacific is marked by rapid product innovation adoption in urban centers, expanding private clinic networks and strong manufacturing ecosystems for polymers and device components. However, regional variations in regulatory harmonization and reimbursement mean that commercial approaches must balance centralized launches with country-specific clinical evidence and engagement plans. Across all regions, governments and health systems are increasingly prioritizing equitable access and long-term safety monitoring, which in turn raises the strategic value of real-world evidence programs and durable local partnerships.

Company strategies and competitive dynamics shaping product innovation, manufacturing footprints, regulatory pathways and partnership models in the device sector

Leading companies in the contraceptive drug-eluting device space are converging on a set of strategic priorities that shape competitive dynamics. Product differentiation is being driven by polymer selection and release kinetics, procedural ease of insertion and removal, and integrated patient support services that include digital follow-up and adherence tools. Firms that invest early in scalable sterile manufacturing, robust quality systems and diversified component sourcing gain advantages in speed-to-market and margin resilience.

Partnering strategies are also prominent: licensors, contract manufacturers and clinical research organizations are often engaged to compress development timelines, share regulatory risk and extend geographic reach. Companies with established relationships across clinical networks and family planning programs tend to secure earlier adoption, particularly when combined with provider training and reimbursement support. Regulatory strategy is an increasingly strategic discipline, with leading firms designing pre-submission engagements and phased post-market evidence plans to align with varying global regulatory expectations.

Finally, innovation priorities include not only material science and device form factors but also patient experience improvements and lifecycle services that lower total cost of care. Firms that align R&D, commercial and policy engagement to deliver measurable clinical advantages and operational dependability will be best positioned to capture sustainable value.

Actionable recommendations for industry leaders to accelerate innovation, strengthen supply chains, align regulatory strategy and expand patient access

Industry leaders should adopt a pragmatic, phased approach that balances near-term operational resilience with long-term innovation. First, prioritize supply chain resilience by identifying critical polymer and component suppliers, qualifying secondary sources, and assessing the feasibility of regional manufacturing hubs to mitigate tariff and logistics risks. Investing in validated contract manufacturing relationships and redundant sterilization capacity can reduce disruption risk while preserving capital efficiency.

Second, integrate regulatory and clinical evidence planning from project inception. Early engagement with regulators and the design of real-world evidence strategies will shorten approval timelines and facilitate broader payer conversations. Manufacturers should build registries and post-market data collection into launch budgets to demonstrate safety, user satisfaction and comparative outcomes across age and parity cohorts.

Third, tailor commercial models to segmentation insights: align product duration and ring cadence with demographic and parousity preferences, and customize training resources for family planning centers and OB-GYN clinics. Leverage digital health tools to extend counseling and follow-up, thereby lowering clinic burden and improving adherence. Finally, pursue flexible pricing and distribution arrangements with hospital pharmacies, online pharmacies and retail channels to enhance access while protecting margins. Taken together, these actions create a resilient foundation for scaling responsibly and competitively.

Research methodology explaining data collection, primary interviews, clinical and regulatory intelligence, supply chain mapping and qualitative scenario development

The research combines structured primary interviews, targeted secondary intelligence and synthesis of clinical, regulatory and supply chain data to create a robust evidence base. Primary research included structured interviews with clinicians, procurement specialists, polymer suppliers, contract manufacturers and regulatory advisors to capture frontline perspectives on device usability, procurement barriers and manufacturing constraints. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, patent landscape signals and clinical trial registries to triangulate product performance and approval pathways.

Analytical methods incorporated thematic coding of qualitative interviews, crosswalks between product attributes and end-user needs, and supply chain mapping to identify single points of failure and sourcing concentration risk. Scenario analysis was used to evaluate tariff and policy shifts, testing implications for manufacturing location decisions and distribution channel economics. Quality control measures included cross-validation of critical inputs, expert panel review of key assumptions and iterative feedback loops with clinical advisors to ensure that conclusions reflect practical clinical realities rather than theoretical constructs.

This mixed-methods approach delivers actionable insights by connecting material science and device engineering to clinical workflows, reimbursement realities and operational logistics, thereby supporting evidence-based strategic choices.

Concluding perspectives synthesizing clinical, technological and commercial implications for the future trajectory of contraceptive drug-eluting devices

In conclusion, contraceptive drug-eluting devices present a compelling convergence of clinical value, material innovation and commercial opportunity, yet realizing that potential requires coordinated action across product development, regulatory strategy and supply chain management. Advances in biodegradable and non-biodegradable polymers expand the toolbox for tailoring duration and user experience, while evolving care models and digital support expand channels for counseling and follow-up.

Strategic imperatives include securing diversified supply chains, embedding real-world evidence into launch plans, and aligning product features with demographic and end-user segmentation to maximize clinical relevance. Geopolitical developments and tariff measures add urgency to resilience planning but also create incentives for regional manufacturing and partnership models that can improve responsiveness and reduce lead times. Ultimately, organizations that marry technological differentiation with operational discipline and patient-centered commercialization will set the standard for sustainable adoption and meaningful public health impact.

The path forward will be iterative, requiring continuous monitoring of regulatory shifts, clinical outcomes and supply dynamics, but the combination of targeted investment and disciplined execution can unlock durable value across clinical, commercial and policy dimensions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Drug Eluting Devices Market, by Product Type

  • 8.1. Implant
  • 8.2. Intrauterine System
  • 8.3. Vaginal Ring

9. Contraceptive Drug Eluting Devices Market, by Technology

  • 9.1. Biodegradable Polymer
    • 9.1.1. PLA
    • 9.1.2. PLGA
  • 9.2. Non-Biodegradable Polymer
    • 9.2.1. Ethylene Vinyl Acetate
    • 9.2.2. Silicone

10. Contraceptive Drug Eluting Devices Market, by End User

  • 10.1. Clinics
    • 10.1.1. Family Planning Centers
    • 10.1.2. OB-GYN Clinics
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Specialty Centers

11. Contraceptive Drug Eluting Devices Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Contraceptive Drug Eluting Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Contraceptive Drug Eluting Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Contraceptive Drug Eluting Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Contraceptive Drug Eluting Devices Market

16. China Contraceptive Drug Eluting Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Actavis plc
  • 17.6. Agile Therapeutics, Inc.
  • 17.7. Allergan plc
  • 17.8. Amgen Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Bayer AG
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. Eli Lilly and Company
  • 17.13. Evofem Biosciences, Inc.
  • 17.14. GlaxoSmithKline plc
  • 17.15. HRA Pharma
  • 17.16. Johnson & Johnson
  • 17.17. Merck & Co., Inc.
  • 17.18. Mylan N.V.
  • 17.19. Novartis AG
  • 17.20. Novo Nordisk A/S
  • 17.21. Pfizer Inc.
  • 17.22. Roche Holding AG
  • 17.23. Sanofi S.A.
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Warner Chilcott plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY VAGINAL RING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY VAGINAL RING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY VAGINAL RING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLGA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLGA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PLGA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY FAMILY PLANNING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OB-GYN CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OB-GYN CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OB-GYN CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY NON-BIODEGRADABLE POLYMER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CONTRACEPTIVE DRUG ELUTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)